Nikolić-Vukosavljević D, Markićević M, Grujić-Adanja G, Petrović A, Kanjer K, Nesković-Konstantinović Z
Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Pasterova 14, 11 000, Belgrade, Serbia and Montenegro.
Clin Exp Metastasis. 2005;22(4):363-8. doi: 10.1007/s10585-005-1265-8.
In order to address the heterogeneity of the pT1 breast cancer stages, we have been examining the natural and the clinical course of disease in relation to cathepsin D expression, as a molecular marker for the tumor progression that leads to metastasis. The original aim of our pilot study was to determine whether it was possible to distinguish high-risk from low-risk patients, on the basis of nonestrogen- vs. estrogen-regulated cathepsin D expression. Our results showed that estrogen-regulated cathepsin D expression could be useful as surrogate marker of node-positive status. Further, during the natural course of disease, none of 7 pT1N0 patients with tumors bearing nonestrogen-regulated cathepsin D expression developed metastasis. During the clinical course of disease, nonestrogen-regulated cathepsin D expression defined low-risk while estrogen-regulated cathepsin D expression defined high-risk pT1N+ subgroup of patients. Although there is no consensus with respect to metastasis-related prognostic value of cathepsin D expression, our pilot study implies its prognostic value in pT1 breast cancer patients and supports the hypothesis that cathepsin D may promote metastasis in this early stage of disease.
为了应对pT1期乳腺癌分期的异质性，我们一直在研究疾病的自然病程和临床病程与组织蛋白酶D表达的关系，组织蛋白酶D表达作为肿瘤进展导致转移的分子标志物。我们初步研究的最初目的是确定能否基于非雌激素调节与雌激素调节的组织蛋白酶D表达，区分高风险和低风险患者。我们的结果表明，雌激素调节的组织蛋白酶D表达可作为淋巴结阳性状态的替代标志物。此外，在疾病的自然病程中，7例肿瘤具有非雌激素调节的组织蛋白酶D表达的pT1N0患者均未发生转移。在疾病的临床病程中，非雌激素调节的组织蛋白酶D表达定义为低风险，而雌激素调节的组织蛋白酶D表达定义为高风险的pT1N+亚组患者。尽管关于组织蛋白酶D表达与转移相关的预后价值尚无共识，但我们的初步研究表明其在pT1期乳腺癌患者中的预后价值，并支持组织蛋白酶D可能在疾病的这一早期阶段促进转移的假说。
